Why the study?
Do ACE inhibitors, ARBs, and bradykinin receptor activators provide protective effectiveness in diabetic retinopathy?
Do ACE inhibitors, ARBs, and bradykinin receptor activators provide protective effectiveness in diabetic retinopathy?
This review highlights the potential of targeting the renin-angiotensin and kallikrein-kinin systems, including ACE inhibitors, ARBs, and bradykinin receptor activators, for the treatment of diabetic retinopathy.
May support ACEi/ARB use in diabetic retinopathy; leaves open selective bradykinin activation pending prospective trials.
This brief review describes how two complex systems, the renin-angiotensin system (RAS) and the kallikrein-kinin system (KKS), affect the retina. It emphasises the important physiological actions of components of these systems, the protective effectiveness of angiotensin I converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) in diabetic retinopathy and suggests as well the therapeutic possibilities for treatment of diabetic retinopathy by selective activation of bradykinin receptors (B1 and B2).
No takes yet. Share an insight, caveat, or question.
Rajko Igić (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: